Rachel Abbott
Chief Executive Officer Pan Cancer T
Seminars
Wednesday 25th February 2026
Industry Leaders Fireside Chat: Navigating Europe’s Cell Therapy Landscape Amid Investment Pressures, Novel Approaches, & Opportunities for Patient Access
8:30 am
- Discuss how investment headwinds are shaping company strategies and what it takes to sustain progress in Europe
- Highlight the most promising scientific advances, including novel indications, armouring strategies, and in-vivo approaches
- Explore how patient access models, from point-of-care manufacturing to evolving reimbursement pathways, can unlock future growth
Thursday 26th February 2026
Advancing Next-Generation TCR Therapies Targeting ROPN1 to Address Triple-Negative Breast Cancer
11:30 am
- Introduce the rationale for targeting ROPN1 as a novel and tumour-specific antigen in TNBC
- Highlight how next-generation TCR engineering enhances specificity and potency against hard-to-treat solid tumours
- Discuss translational and clinical development plans to demonstrate safety, efficacy, and durable responses in TNBC patients
New Data
